What is small cell neuroendocrine carcinoma of the cervix?
Small cell neuroendocrine carcinoma of the cervix is a rare and aggressive type of cervical cancer. The cervix is the lower, narrow part of the womb that opens into the vagina. In this cancer, the tumour cells are small and behave like neuroendocrine cells, cells that share features with both nerve cells and hormone-producing cells.
The disease looks and behaves much like small cell lung cancer. It grows fast and tends to spread early through the blood and lymph vessels to lymph nodes, the lungs, liver, bones and brain. For that reason, treatment usually combines chemotherapy with surgery or radiotherapy, even when the cancer seems to be confined to the cervix.
Neuroendocrine carcinomas make up only about 1-2% of all cervical cancers. Most of them, about four in five, are of the small cell type (Tempfer et al., 2018). Like common cervical cancer, it is usually linked to human papillomavirus (HPV) infection (Chao et al., 2023).
How it differs from common cervical cancer
Most cervical cancers are squamous cell carcinomas or adenocarcinomas, described on our page on cervical cancer. Small cell neuroendocrine carcinoma shares the HPV link but differs in important ways.
| Feature | Squamous cell carcinoma or adenocarcinoma | Small cell neuroendocrine carcinoma |
|---|---|---|
| Share of cervical cancers | The vast majority | About 1% |
| Growth | Often slower | Very fast |
| Spread | Often stays in the pelvis for a long time | Early spread to distant organs |
| Screening | Often found early by smear tests | Smear tests may miss it |
| Chemotherapy | Cisplatin with radiotherapy | Etoposide plus platinum, as in small cell lung cancer |
| Outlook | Good for early stages | Guarded even in early stages |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade neuroendocrine carcinoma of the cervix |
| How common | About 1% of cervical cancers |
| Typical age | Often women in their 30s to 50s |
| Main cause | HPV infection, especially HPV type 18 |
| Usual first sign | Abnormal vaginal bleeding |
| Spread | Lymph nodes, lungs, liver, bone and brain |
| Main treatments | Etoposide-platinum chemotherapy with surgery or chemoradiotherapy |
| Outlook | Guarded; better when found at an early stage |
2. Types
Neuroendocrine tumours of the cervix
| Type | Description | Share |
|---|---|---|
| Small cell neuroendocrine carcinoma | Small cells with scant cytoplasm | About 80% of cervical neuroendocrine carcinomas |
| Large cell neuroendocrine carcinoma | Larger cells with more cytoplasm | About 12% |
| Mixed carcinoma | Neuroendocrine carcinoma together with adenocarcinoma or squamous cancer | A minority |
| Neuroendocrine tumour (carcinoid) | Well-differentiated; very rare in the cervix | Rare |
The proportions come from a large systematic review of more than 3,500 cases (Tempfer et al., 2018).
3. Causes and risk factors
| Factor | Notes |
|---|---|
| HPV infection | Found in most tumours; HPV 18 is the most frequent type |
| Smoking | Raises the risk of cervical cancer in general |
| Weakened immunity | Such as HIV infection, which makes HPV harder to clear |
| Lack of screening and vaccination | Increases the risk of all HPV-related cervical cancers |
| Inherited factors | No known inherited syndrome |
Why does it spread so early?
Small cell carcinomas divide very rapidly and readily invade small blood vessels and lymph channels. Tumour cells can therefore reach distant organs while the tumour in the cervix still looks small. This is why chemotherapy that treats the whole body is part of treatment for almost every woman with this cancer.
Can the HPV vaccine prevent it?
Because most of these cancers are caused by high-risk HPV types that are covered by current vaccines, HPV vaccination is expected to reduce this cancer as well as common cervical cancer.
4. How does it look
On examination
| Finding | Description |
|---|---|
| Cervix | A visible mass, ulcer or bleeding area; sometimes the cervix looks enlarged and firm |
| Inside the canal | Tumours may grow inside the cervical canal and be hard to see |
| Pelvic examination | May show spread to the vagina or the tissues beside the womb |
On scans
| Scan | Purpose |
|---|---|
| Pelvic MRI | Shows the size of the tumour and spread into nearby tissues |
| CT or PET-CT | Checks lymph nodes and distant organs |
| Brain MRI | Considered by some teams, as brain spread is more frequent than with common cervical cancer |
Under the microscope
| Feature | Description |
|---|---|
| Cells | Small, round to oval cells with very little cytoplasm |
| Nuclei | Finely granular chromatin, nuclei moulding against each other |
| Activity | Many dividing cells and areas of cell death |
| Neuroendocrine markers | Synaptophysin, chromogranin, CD56 and INSM1 |
| Proliferation | Very high Ki-67 index |
| HPV testing | Usually positive for high-risk HPV |
In the systematic review, synaptophysin was the marker most often positive, in about four of five tested tumours (Tempfer et al., 2018).
5. Symptoms
Common symptoms
- Bleeding after sex
- Bleeding between periods or after the menopause
- Unusual vaginal discharge, which may be watery, blood-stained or smelly
- Pain in the pelvis
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Back or leg pain, leg swelling | Spread to pelvic or abdominal lymph nodes |
| Difficulty passing urine or opening bowels | Pressure from a large tumour |
| Cough or breathlessness | Spread to the lungs |
| Bone pain | Spread to bone |
| Headaches, confusion or seizures | Spread to the brain |
| Flushing, low sodium or other hormone effects | Rare hormone release by the tumour |
When to seek medical advice
See a doctor about any unexplained vaginal bleeding, especially after sex or after the menopause. Do not wait for your next screening test, as smear tests can miss this cancer.
6. Diagnosis
| Step | What is done |
|---|---|
| Pelvic examination | Checks the cervix and nearby tissues |
| Colposcopy and biopsy | Takes tissue from the cervix |
| Pathology with neuroendocrine stains | Confirms the diagnosis |
| Pelvic MRI | Measures local spread |
| PET-CT or CT of chest, abdomen and pelvis | Looks for distant spread |
| Brain MRI | Considered in many cases |
| Blood tests | Blood count, kidney and liver function, sodium |
Staging
Doctors use the FIGO staging system for cervical cancer.
| Stage | Simplified meaning |
|---|---|
| Stage I | Confined to the cervix |
| Stage II | Spread beyond the cervix to the upper vagina or tissues beside the womb, but not to the pelvic wall |
| Stage III | Spread to the lower vagina, pelvic wall or pelvic or para-aortic lymph nodes, or blocking a kidney |
| Stage IV | Spread to the bladder or bowel, or to distant organs |
In the review, about half of all women were diagnosed at an early stage and half at a late stage (Tempfer et al., 2018).
7. Treatment
There are no randomised trials for this rare cancer. Treatment is based on case series, expert guidelines and experience with small cell lung cancer. It should be planned by a gynaecological oncology team.
Main approaches
| Stage | Common approach |
|---|---|
| Early stage, small tumour | Radical hysterectomy with lymph node removal, followed by etoposide-platinum chemotherapy, with or without radiotherapy |
| Early stage, larger tumour | Chemotherapy first, then surgery, or chemoradiotherapy |
| Locally advanced | Chemoradiotherapy with etoposide-platinum, often followed by further chemotherapy; surgery in selected women |
| Metastatic | Etoposide-platinum chemotherapy; immunotherapy or trials |
| Recurrent | Other chemotherapy regimens such as topotecan, paclitaxel and bevacizumab; trials |
Chemotherapy
The most widely used regimen is cisplatin or carboplatin with etoposide, the same combination used for small cell lung cancer (Tempfer et al., 2018).
| Aspect | Details |
|---|---|
| Drugs | Cisplatin or carboplatin plus etoposide |
| Number of cycles | Usually 4-6 |
| Timing | Before or after surgery, or with radiotherapy |
Surgery
A study combining data from US and Chinese registries found that surgery was linked to better survival, including in some women with locally advanced disease (Chu et al., 2023). This differs from common cervical cancer, where larger tumours are usually treated with chemoradiotherapy alone.
Radiotherapy
| Type | Use |
|---|---|
| External beam radiotherapy | Treats the pelvis and lymph nodes |
| Brachytherapy | Internal radiotherapy placed in the cervix or vagina |
| Brain radiotherapy | For brain spread; preventive treatment is sometimes discussed |
An Italian study of 27 women having surgery and chemotherapy found that adding brachytherapy was linked to better survival (Valenza et al., 2023).
Immunotherapy
Checkpoint inhibitors work in small cell lung cancer and in common cervical cancer. Their role in small cell cervical cancer is still being studied, and evidence so far comes from case reports (Chao et al., 2023).
Side effects
| Treatment | Possible side effects |
|---|---|
| Radical hysterectomy | Loss of fertility, bladder problems, leg swelling after node removal |
| Etoposide-platinum | Hair loss, low blood counts, infection risk, sickness, numbness, hearing changes |
| Pelvic radiotherapy | Diarrhoea, bladder irritation, vaginal narrowing, early menopause |
| Immunotherapy | Inflammation of the skin, gut, liver, lungs or hormone glands |
Fertility and menopause
Treatment usually ends the possibility of pregnancy and causes early menopause in younger women. Ask your team about fertility preservation and hormone replacement. Unlike some hormone-sensitive cancers, HRT is often considered safe after treatment for cervical cancer, but discuss it with your oncologist.
8. Outlook (prognosis)
The outlook is more guarded than for common cervical cancer at the same stage.
| Source | Main finding |
|---|---|
| Systematic review, more than 3,500 cases | Average survival around 40 months; average time free of recurrence about 16 months (Tempfer et al., 2018) |
| Italian series, 27 women having surgery | Median overall survival 33 months (Valenza et al., 2023) |
| US and Chinese registries, 1,288 women | Surgery linked to longer survival (Chu et al., 2023) |
Factors that affect the outlook
| Factor | Effect |
|---|---|
| Stage | The most important factor |
| Tumour size | Smaller tumours do better |
| Lymph node spread | Poorer outlook |
| Complete treatment | Women who finish combined treatment do better |
9. Follow-up
| Period | Typical checks |
|---|---|
| Years 1-2 | Every 3 months: examination and scans as advised |
| Years 3-5 | Every 6 months |
| After 5 years | Yearly |
Scans are often used more often than for common cervical cancer because of the higher risk of distant spread.
10. Living with small cell neuroendocrine carcinoma of the cervix
- Use vaginal dilators after radiotherapy if advised, to reduce narrowing
- Report new symptoms such as headaches, cough or bone pain promptly
- Look after your bones and heart if you have early menopause
- Stop smoking, which also helps healing and recovery
- Ask for psychosexual support if sex has become difficult
- Seek support from gynaecological cancer charities
Coping with the diagnosis
Hearing that you have a rare, fast-growing cancer can be frightening, particularly for younger women who may be caring for children or planning a family. Specialist gynaecological oncology nurses can explain each step of treatment and help you plan around it. Psychological support, peer support groups and financial advice services are available through most cancer centres.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is this the same as small cell lung cancer? | No, it starts in the cervix, but it behaves similarly and is treated in a similar way |
| Why did my smear test not find it? | It often grows inside the canal and sheds few abnormal cells |
| Is it caused by HPV? | Usually, yes |
| Can I have children after treatment? | Usually not; discuss options before treatment |
| Do I need a brain scan? | Many teams recommend one because brain spread is more common than in other cervical cancers |
| Is immunotherapy an option? | It is being studied; ask about trials |
| Will I need chemotherapy even if surgery removes everything? | Usually yes, because hidden cancer cells may already have spread |
| Is it more common in older women? | No; it often affects younger women than other gynaecological cancers do |
12. Questions to ask your care team
- Is my cancer small cell or large cell neuroendocrine carcinoma?
- What stage is it, and has it spread?
- Do I need a brain MRI?
- Will I have surgery, chemoradiotherapy or both?
- Which chemotherapy do you recommend, and for how long?
- How will treatment affect my fertility, menopause and sex life?
- Are there clinical trials I could join?
Resources
- Chao, A. et al. (2023) ‘Small cell neuroendocrine carcinoma of the cervix: from molecular basis to therapeutic advances’, Biomedical Journal, 46(5), 100633.
- Chu, T. et al. (2023) ‘The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry’, Lancet Oncology, 24(6), pp. 701-708.
- Tempfer, C.B. et al. (2018) ‘Neuroendocrine carcinoma of the cervix: a systematic review of the literature’, BMC Cancer, 18(1), 530.
- Valenza, C. et al. (2023) ‘Multimodal treatment for resectable neuroendocrine carcinoma of the cervix’, Endocrine-Related Cancer, 30(10), e230112.
- National Cancer Institute (2026) Cervical Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.